Summary

The role of Trastuzumab deruxtecan CNS stage 4 breast Ca HER2+ (DEBBRAH study),Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03, the role of Tucatinib in CNS and Dato-DXd : as a new drug anti-TROP2

User

Dr. Jamil Asselah

Medical Oncologist - McGill University Health ...

Montreal,

Medical Oncologist - McGill University Health Centre (MUHC) President of the Executive Scientific Committee, McPeak-Sirois Group

Comments (1)

  •
    Sean Mollitt

    test